arrow
B

Bradley P. Dixon

renal section
H指数:26
被引数:2,847

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment burden, healthcare experiences, and health-related quality of life among youth with chronic kidney disease treated for hypertension

慢性肾脏病高血压治疗青年患者的治疗负担、医疗体验及健康相关生活质量

2026-09-240
PRE
Blood Pressure Control in Adolescents With Chronic Kidney Disease and Risk of Kidney Failure in Young Adulthood

青少年慢性肾脏病患者血压控制与青年期肾脏衰竭风险

2026-05-050
OAAI
Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis

pegcetacoplan治疗C3肾小球病或原发性免疫复合物膜增生性肾小球肾炎的青少年:III期VALIANT亚组分析

2026-05-011
PRE
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

Pegcetacoplan在C3肾小球病和免疫复合物型MPGN中的试验

2025-12-044
PRE
Using a multi-institutional pediatric learning health system to characterize induction therapy for incident lupus nephritis in children

采用多机构儿科学习健康系统来表征儿童新发狼疮肾炎的诱导治疗

2025-12-010
PRE
Targeted treatment with pegcetacoplan for adolescents with C3G or primary (idiopathic) IC-MPGN in the VALIANT Phase 3 trial

VALIANT III期临床试验中,使用pegcetacoplan针对青少年C3G或原发性(特发性)IC-MPGN的靶向治疗

2025-10-010
OAAI
Kidney Function Following COVID-19 in Children and Adolescents

COVID-19后儿童和青少年的肾功能

2025-04-110
OA
An expert discussion on the atypical hemolytic uremic syndrome nomenclature- - identifying a road map to precision: a report of a National Kidney Foundation Working Group OPEN
2024-09-011
OAAI
Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study
2024-08-161
OAAI
Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials
2024-08-013
OAAI
The Preserving Kidney Function in Children With CKD (PRESERVE) Study: Rationale, Design, and Methods
2023-11-011
OAAI